Doxil/Eloxatin® May Provide a Treatment Option in Advanced, Recurrent Ovarian C.
According to a recent article published in Gynecologic Oncology, the chemotherapy combination consisting of Doxil® (pegylated liposomal doxorubicin) plus Eloxatin® (oxaliplatin) may provide an effective treatment option for patients with advanced ovarian cancer that has progressed or recurred following treatment including a platinum chemotherapy agent.
Ovarian cancer is one of the most deadly gynecologic cancers because it tends to be diagnosed at a late stage (once the cancer has spread), making it difficult to cure. Although advanced ovarian cancer (cancer that has spread from the ovary to other sites in the body) may respond to initial therapy, it often recurs (recurrent ovarian cancer).
Patients with recurrent ovarian cancer have dismal long-term outcomes with standard treatment approaches. Researchers continue to evaluate new chemotherapy combinations and therapeutic approaches in order to improve the duration of survival and/or quality of life for patients with this disease.
Researchers in Italy conducted this multi-center phase II study to further evaluate the efficacy and safety of the combination of Doxil and Eloxatin for the treatment of patients with recurrent ovarian cancer. Participants in the study included women with recurrent ovarian cancer who had previously been treated with a regimen containing a platinum agent (Paraplatin® [carboplatin] or Platinol® [cisplatin]).
- Anticancer responses occurred in 54% of patients.
- Anticancer responses occurred in 67% of patients who had achieved an anticancer response for at least 6 months following prior platinum-based therapy.
- Anticancer responses occurred in 29% of patients who experienced cancer progression within 6 months of treatment following prior platinum-based therapy.
- Median overall survival was nearly 16 months.
- Median time to cancer progression was 7.3 months.
- Most side effects were mild and manageable.
The researchers concluded that the chemotherapy combination consisting of Doxil/Eloxatin may provide anticancer responses in patients with advanced, recurrent ovarian cancer. Patients with recurrent ovarian cancer may wish to speak with their physician regarding their individual risks and benefits of participation in a clinical trial further evaluating Doxil/Eloxatin or other novel therapeutic approaches.
Reference: Nicoletto M, Falci C, Pianalto D, et al. Phase II Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Relapsed Advanced Ovarian Cancer. Gynecologic Oncology. 2006; 100: 318-323.
Related News:Doxil® Receives Full Approval for Recurrent Ovarian Cancer (3/2/05)
Copyright © 2018 CancerConnect. All Rights Reserved.